We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+22.33%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$385B
AUM Growth
+$32.1B
Cap. Flow
-$35.1B
Cap. Flow %
-9.14%
Top 10 Hldgs %
30.5%
Holding
11,975
New
1,989
Increased
4,461
Reduced
4,218
Closed
1,130

Sector Composition

Rank Sector Weight
1 Technology 3.66%
2 Healthcare 3.16%
3 Industrials 2.01%
4 Financials 1.98%
5 Consumer Discretionary 1.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXK
8526
PUT
Endeavour Silver
EXK
$2.83B
$379K ﹤0.01%
75,100
+27,500
+58% +$102K
FXO icon
8527
First Trust Financials AlphaDEX Fund
FXO
$1.14B
$379K ﹤0.01%
11,061
-16,043
-59% -$491K
PMVP icon
8528
PMV Pharmaceuticals
PMVP
$63.5M
$379K ﹤0.01%
6,155
-7,220
-54% -$283K
SUPN icon
8529
Supernus Pharmaceuticals
SUPN
$2.77B
$379K ﹤0.01%
+15,076
New +$324K
QTTB icon
8530
PUT
Q32 Bio
QTTB
$464M
$379K ﹤0.01%
1,867
-50
-3% -$9.66K
BDSX icon
8531
Biodesix
BDSX
$248M
$378K ﹤0.01%
+938
New +$292K
FRO icon
8532
CALL
Frontline
FRO
$8.85B
$378K ﹤0.01%
60,700
-61,100
-50% -$393K
SFT
8533
PUT
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$378K ﹤0.01%
4,570
+1,880
+70% +$174K
NBEV
8534
CALL
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$378K ﹤0.01%
143,600
-7,300
-5% -$19.8K
HR icon
8535
PUT
Healthcare Realty
HR
$6.84B
$377K ﹤0.01%
+13,700
New +$361K
VHC icon
8536
CALL
VirnetX Holding Corp
VHC
$63.1M
$377K ﹤0.01%
3,740
+1,190
+47% +$129K
EVA
8537
CALL
DELISTED
Enviva Inc.
EVA
$377K ﹤0.01%
+8,300
New +$362K
BMI icon
8538
CALL
Badger Meter
BMI
$4.03B
$376K ﹤0.01%
4,000
-3,900
-49% -$311K
DGRO icon
8539
iShares Core Dividend Growth ETF
DGRO
$43.5B
$376K ﹤0.01%
8,397
-44,924
-84% -$1.91M
PBA icon
8540
PUT
Pembina Pipeline
PBA
$27.6B
$376K ﹤0.01%
15,900
-3,100
-16% -$72.9K
SBLK icon
8541
CALL
Star Bulk Carriers
SBLK
$3.22B
$376K ﹤0.01%
42,600
+20,400
+92% +$151K
SLRC icon
8542
CALL
SLR Investment Corp
SLRC
$715M
$376K ﹤0.01%
21,500
+7,400
+52% +$125K
BCLI
8543
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$375K ﹤0.01%
5,527
-80
-1% -$10.9K
DGICA icon
8544
Donegal Group Class A
DGICA
$714M
$375K ﹤0.01%
26,609
+7,221
+37% +$104K
HEI.A icon
8545
CALL
HEICO Corp Class A
HEI.A
$37.2B
$375K ﹤0.01%
+3,200
New +$348K
SRNE
8546
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$375K ﹤0.01%
54,980
-298
-0.5% -$2.39K
CALA
8547
PUT
DELISTED
Calithera Biosciences, Inc
CALA
$375K ﹤0.01%
3,815
+3,285
+620% +$288K
SYV
8548
DELISTED
SPDR MFS Systematic Value Equity ETF of SSgA Active Trust
SYV
$375K ﹤0.01%
5,374
-2,691
-33% -$176K
AGEN
8549
PUT
Agenus
AGEN
$290M
$374K ﹤0.01%
5,997
+1,045
+21% +$77.5K
MDU icon
8550
PUT
MDU Resources
MDU
$4.32B
$374K ﹤0.01%
37,344
+526
+1% +$4.92K

Similar funds

Citadel Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Citadel Advisors held 11,975 positions worth $385B, up 9.1% from $353B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Citadel Advisors withdrew a net $35.1B in Q4 2020, closing 1,130 positions and reducing 4,218 holdings. Its most notable exit was Immunomedics Inc, an estimated $213M position sold in full.

By sector, the portfolio is most concentrated in Technology at 3.7% of assets, up from 3% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Citadel Advisors opened a new position in S&P Global worth $114M.

  • Citadel Advisors's largest Q4 2020 buy was S&P Global: 345,785 shares worth $114M.
  • Citadel Advisors added most to iShares Core S&P 500 ETF in Q4 2020, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2020 reduction was Amazon, cutting an estimated $1.55B.
  • Citadel Advisors fully exited Immunomedics Inc in Q4 2020, selling an estimated $213M.
  • Citadel Advisors's ten largest holdings make up 31% of its $385B portfolio in Q4 2020.
  • Citadel Advisors opened 1,989 new positions and closed 1,130 in Q4 2020.
  • Citadel Advisors's portfolio value rose 9.1% quarter-over-quarter to $385B.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.